Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy

Next Previous
Trial Profile

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 24 Jun 2020 Results assessing biomarkers prognostic of clinical response to regorafenib in patients with metastatic colorectal cancer, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
  • 09 Aug 2018 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
  • 09 Aug 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top